Medpro Pharrmaceutica, a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa, has entered into a collaboration with Teva Pharmaceuticals, an affiliate of Israel’s Teva Pharmaceutical Industries Ltd.
Cipla Medpro will exclusively market Teva’s broad pharmaceutical product portfolio in South Africa. The collaboration with Teva is restricted to the territory of South Africa and is a sales and distribution arrangement. It will focus on the therapeutic areas of oncology, central nervous system, women’s health, cardiovascular, ophthalmology and other specialty products.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Founded in 1935, Cipla is a global pharmaceutical company which declares its goal to be to ensure that no patient shall be denied access to high quality and affordable medicine and support.
Cipla Medpro calls itself a leading provider of affordable medicines to the public and private sectors. It manufactures pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.
“This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines, ” said Paul Miller, Chief Executive Officer of Cipla Medpro.
“Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans, ” concluded Subhanu Saxena, Managing Director and Global Chief Executive Officer of Cipla Limited.
The collaboration is subject to approval by the Competition Commission of South Africa.